MET and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib, a halogenated TKI with potent activity against BCR-ABL and other tyrosine kinases, has been effective in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [6,14] Foretinib, a halogenated TKI targeting MET, VEGFR, and other kinases, has shown efficacy in various solid tumors, including renal cell carcinoma and hepatocellular carcinoma [15].